Genmab | GEN - Net Income


Genmab reported DKK31M in Net Income for its fiscal quarter ending in December of 2025.





Net Income Change Date
Agios Pharmaceuticals USD -99.11M 8.93M Mar/2026
Almirall EUR 19.58M 7M Dec/2025
Amarin USD -1.22M 6.51M Dec/2025
Amgen USD 1.82B 486M Mar/2026
argenx SE USD 366M 166.95M Mar/2026
AstraZeneca USD 3.08B 754M Mar/2026
Bayer EUR 2.76B 6.52B Mar/2026
BioMarin Pharmaceutical USD 105.53M 152.1M Mar/2026
Demant DKK 427M 690M Dec/2025
Exelixis USD 210.47M 34.06M Mar/2026
Fresenius Medical Care EUR 118M 209M Mar/2026
Genmab DKK 31M 370M Dec/2025
GlaxoSmithKline GBP 1.74B 1.1B Mar/2026
GN Store Nord DKK -955M 1.3B Mar/2026
GRIFOLS EUR 73M 25.25M Mar/2026
Hikma Pharmaceutical USD 164M 45M Dec/2025
Insmed USD -163.56M 164.92M Mar/2026
Lakefront Biotherapeutics EUR 14.49M 767.65M Mar/2026
Lonza CHF 426M 119M Jun/2025
Merck EUR 319M 583M Dec/2025
Novartis USD 3.16B 747M Mar/2026
Regeneron Pharmaceuticals USD 727.2M 117.4M Mar/2026
Roche Holding CHF 5.47B 1.76B Dec/2025
Sanofi EUR 1.61B 2.42B Mar/2026
UCB EUR 1.08B 608M Dec/2025